Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl

Nadir Testosterone Within First Year of Androgen-Deprivation Therapy (ADT) Predicts for Time to Castration-Resistant Progression: A Secondary Analysis of the PR-7 Trial of Intermittent Versus Continuous ADT

(2015) Laurence Klotz et al.   JOURNAL OF CLINICAL ONCOLOGY

Bench-to-bedside development of agonists and antagonists of luteinizing hormone–releasing hormone for treatment of advanced prostate cancer

(2015) Ferenc G. Rick et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Clinical pharmacology and regulatory consequences of GnRH analogues in prostate cancer

(2014) Niels Eckstein et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Is High-Dose Leuprorelin Acetate Effective and Safe in Asian Men with Prostate Cancer? An Open-Label, Non-Comparative, Multi-Center Clinical Trial

(2014) Seung-Hwan Lee et al.   YONSEI MEDICAL JOURNAL

Effects of Serum Testosterone Levels After 6 Months of Androgen Deprivation Therapy on the Outcome of Patients With Prostate Cancer

(2013) Valentina Bertaglia et al.   Clinical Genitourinary Cancer

Variations of serum testosterone levels in prostate cancer patients under LH-releasing hormone therapy: an open question

(2012) Leonardo Oliveira Reis   ENDOCRINE-RELATED CANCER

Goserelin versus leuprolide in the chemical castration of patients with prostate cancer

(2012) Élcio Dias Silva et al.   INTERNATIONAL UROLOGY AND NEPHROLOGY

Open, multi-center, phase IV study to assess the efficacy and tolerability of triptorelin in Taiwanese patients with advanced prostate cancer

(2012) Chien-Chang Kao et al.   Journal of the Chinese Medical Association

Lower Testosterone Levels With Luteinizing Hormone-Releasing Hormone Agonist Therapy Than With Surgical Castration: New Insights Attained by Mass Spectrometry

(2012) Tim M. van der Sluis et al.   JOURNAL OF UROLOGY

Encapsulation of Exenatide in Poly-(d,l-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes

(2011) Mary Beth DeYoung et al.   Diabetes Technology & Therapeutics

Efficacy of a Second Line Luteinizing Hormone-Releasing Hormone Agonist After Advanced Prostate Cancer Biochemical Recurrence

(2011) Nathan Lawrentschuk et al.   JOURNAL OF UROLOGY

Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer

(2011) A Spitz et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?

(2009) Massimo Perachino et al.   BJU INTERNATIONAL

Triptorelin 6-Month Formulation in the Management of Patients with Locally Advanced and Metastatic Prostate Cancer

(2009) Eija A. Lundström et al.   CLINICAL DRUG INVESTIGATION

Current advances in research and clinical applications of PLGA-based nanotechnology

(2009) Jian-Ming Lü et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Impact of Surgical and Medical Castration on Serum Testosterone Level in Prostate Cancer Patients

(2009) Giacomo Novara et al.   UROLOGIA INTERNATIONALIS

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

(2008) Laurence Klotz et al.   BJU INTERNATIONAL